Adamax: What the Name Covers and What Is Actually Published

Research-use-only context. This article summarizes published third-party scientific literature and laboratory practice. It is not medical advice, not a therapeutic or performance claim, and not a usage guide. US Prime Peptides products are supplied strictly for in vitro laboratory research and are not for human or veterinary use.

This article answers a narrow question honestly: what does the name "Adamax" refer to, and what has actually been published about it? The short answer is that Adamax is a vendor name for Semax carrying an adamantane group, that PubMed contains no paper on the conjugate itself, and that everything a buyer can verify comes from two adjacent literatures: the Semax parent studies and the chemistry of attaching adamantane to peptides.

What the name "Adamax" covers

Adamax is a catalog name, not a registered or published compound. It describes the heptapeptide Semax (Met-Glu-His-Phe-Pro-Gly-Pro) to which an adamantane cage has been attached, almost always at the N-terminal methionine amine as an adamantane-1-carbonyl (adamantoyl) amide. The name has no International Nonproprietary Name, no PubChem entry, no CAS number of its own, and no entry in any pharmacopeia. A PubMed search for "Adamax" on 20 October 2026 returned 39 records, every one of them about the AdaMax optimizer used in machine learning, and none about a peptide. Searches for "adamantane Semax" and "Semax adamantyl" returned nothing.

That absence matters for how the rest of this article is written. The parent peptide, Semax, has a real literature: a Russian medicinal registration dating to the 1990s, receptor-binding and BDNF studies, and genome-wide expression work in rat ischemia models, all summarized in the Semax research overview. Adamantane conjugation of peptides also has a real literature in medicinal chemistry. What does not exist is a paper that joins the two by making the adamantoyl-Semax conjugate, characterizing it, and testing it in any model. Any claim that Adamax is "more potent" or "longer-lasting" than Semax is therefore an extrapolation from those two separate bodies of work, not a measured result.

Neither Semax nor Adamax is an approved drug in the United States. Semax holds a Russian registration; Adamax holds none anywhere. A research vial sold under this name is a laboratory chemical whose only verifiable description is its certificate of analysis. The Adamax 10 mg listing shows the lot-matched certificate format for the lyophilized form, and the Adamax liquid spray 10 mg / 10 mL listing shows the certificate for the solution format, with the labeled mass per bottle.

The parent: what the Semax literature actually established

The Semax findings most relevant to a conjugate are the ones about binding and breakdown, because those are the properties conjugation is meant to change. Dolotov and colleagues (2006, Journal of Neurochemistry) reported specific, reversible, calcium-dependent binding of tritiated Semax to rat basal forebrain membranes with a dissociation constant near 2.4 nanomolar, and higher BDNF protein in that tissue three hours after exposure. A companion 2006 Brain Research paper reported a 1.4-fold rise in hippocampal BDNF protein with increased TrkB phosphorylation. No receptor has been cloned, so there is no binding assay against which a modified analog could be ranked.

On breakdown, Shevchenko and colleagues (2006, Bioorganicheskaia Khimiia) followed Semax labeled with tritium on the C-terminal proline in rats and reported rapid enzymatic cleavage, with the tripeptide Pro-Gly-Pro dominating the labeled material recovered from tissue. Zolotarev and colleagues (2006, same journal) used evenly tritiated peptide in the presence of nerve cells and identified His-Phe-Pro-Gly-Pro and Pro-Gly-Pro as the main products, which places the first cut at the N-terminal methionine and points to aminopeptidases. That is the rationale a vendor is implicitly relying on: cap the N-terminus and the aminopeptidase cannot start.

The same group tested exactly that idea with a smaller cap. Shevchenko and colleagues (2013, Doklady Biological Sciences) examined the proteolytic stability of N-acetyl Semax in several biological media. And Magri and colleagues (2016, Journal of Inorganic Biochemistry) showed that acetylating the N-terminus is not biologically neutral: it changed the copper(II) coordination from a four-nitrogen to a three-nitrogen/one-oxygen chromophore, shifted the redox potential, and eliminated the reduction in copper-induced toxicity that unmodified Semax produced in SH-SY5Y cells. If a two-carbon acetyl cap changes the chemistry that much, a ten-carbon adamantane cage should be assumed to change it more, in directions nobody has measured.

Adamantane conjugation: what the chemistry literature says it does

Adamantane is a rigid, bulky, highly lipophilic C10H16 cage. Wanka, Iqbal and Schreiner's 2013 Chemical Reviews survey, titled "The lipophilic bullet hits the targets," catalogs its use across medicinal chemistry: amantadine, rimantadine and memantine are adamantane amines, and saxagliptin and vildagliptin carry adamantyl groups. The recurring reasons for adding it are to raise lipophilicity, to fill a hydrophobic pocket, and to shield a nearby bond from enzymes. A 2024 review in Archiv der Pharmazie by Ragshaniya and colleagues updates that catalog.

Three peptide-specific papers show what happens when the cage is attached to a short sequence. Kitagawa and colleagues (1997, Chemical and Pharmaceutical Bulletin) prepared seven [D-Ala2]Leu-enkephalin derivatives carrying an adamantane moiety at the N- or C-terminus by solution-phase synthesis, measured much higher lipophilicity for the C-terminal ester and amide conjugates, and recorded moderate activity in a guinea-pig ileum assay and an in vivo mouse tail-pressure test. Ljungstrom, Knudsen and Nielsen (1999, Bioconjugate Chemistry) attached adamantyl acetic acid to 15-mer peptide nucleic acids and reported greatly improved, but strongly cell-line-dependent, uptake in HeLa, IMR-90 and MDA-MB-453 cells by confocal microscopy. Kapoerchan and colleagues (2010, Chemistry: A European Journal) built an adamantyl amino acid into gramicidin S analogs and used it to tune the balance between antibacterial activity and hemolysis.

Two more are useful for method. Todorov and colleagues (2020, Amino Acids) made hemorphin-4 analogs with an N-terminal adamantyl building block by Fmoc solid-phase synthesis and recorded the infrared lines characteristic of both the adamantane cage and the peptide backbone, a reminder that the conjugate has a spectroscopic signature distinct from the parent. Karle and colleagues (2008, Biopolymers) solved crystal structures of proline-adamantane hybrid cyclic depsipeptides and described the adamantyl groups as providing both membrane permeability and conformational constraint. The common thread is that adamantane reliably raises lipophilicity and changes uptake, but that the biological result depends on where it is attached and on the cell system; none of these papers used Semax.

What conjugation changes on paper, and on a certificate

The expected chemical consequences can be stated without any biological data. An adamantane-1-carbonyl group on the methionine amine adds C11H14O to the formula, raising the mass from about 813.9 to about 976.1 daltons; a direct 1-adamantyl group (no carbonyl) adds C10H15 and gives about 948.1. The free N-terminal amine, its positive charge and its metal-coordinating lone pair are gone. Lipophilicity rises sharply, so the conjugate elutes much later on reverse-phase HPLC than Semax, dissolves less readily in water, and is more prone to aggregation and to adsorption on plastic (see Why Peptides Stick to Plastic). The methionine sulfur is still present and still oxidizable.

The certificate consequence follows directly. A certificate for Adamax must show an observed mass near 976 (or 948), not 814. If the mass-spectrometry identity line reads 813.9 or 814.4, the vial contains Semax. Because mass spectrometry cannot show where on the chain the cage sits, a careful buyer should also ask for the chromatogram and compare the retention time against a Semax reference; a conjugate that co-elutes with Semax is suspect. The logic of reading an identity line is covered in LC-MS Identity Confirmation, and the difference between purity and content, which matters more for a hydrophobic conjugate that may carry extra counter-ion and water, is in Net Peptide Content vs Purity.

The one "Semax derivative" paper, and why it does not fill the gap

A 2025 paper in Acta Naturae by Radchenko and colleagues compared Semax with "its derivative" in APPswe/PS1dE9 transgenic mice, scoring open-field, novel-object-recognition and Barnes-maze behavior and counting amyloid inclusions in cortex and hippocampus by histology. Vendors sometimes point to this paper as evidence for Adamax. It is not. The abstract does not identify the derivative, the authors are from the Institute of Molecular Genetics group that has historically worked on acetylated and glyproline-modified analogs, and nothing in the public record links the compound to an adamantane cage. Until a paper names the structure, gives its mass, and tests it, the Adamax literature remains empty.

The same standard should be applied to any vendor page. Claims that adamantane "increases blood-brain-barrier penetration" are borrowed from the enkephalin and PNA conjugate papers above, which used different peptides and, in the PNA case, found the effect to be cell-line dependent. Claims about "longer half-life" are borrowed from the aminopeptidase logic of the 2006 Zolotarev paper, which never tested a capped analog. Claims about potency have no source at all, because no binding assay for Semax exists and no one has run the BDNF or transcriptome experiments with the conjugate.

How to read a vendor claim about Adamax critically

A practical checklist for a lab buyer or practice manager evaluating any Adamax listing:

1. Ask for the structure. Which atom carries the adamantane, and through what linkage? A listing that cannot answer is selling a name.
2. Check the mass on the certificate. Expect roughly 976 (adamantoyl) or 948 (adamantyl), never 814.
3. Look at retention time. The conjugate should elute well after Semax on the same reverse-phase method.
4. Separate the three literatures. Semax biology, adamantane chemistry, and Adamax itself. Any sentence that starts "studies show Adamax..." should be followed by a PMID; none exists.
5. Take the Magri 2016 result as a warning. Capping the Semax N-terminus changed its copper chemistry and removed a measured cell effect; a larger cap is not a free upgrade.
6. Weigh the solution format accordingly. A hydrophobic conjugate in aqueous solution needs the certificate to state content per bottle and the preservative system, as described in Inside a Peptide Liquid Spray.

None of this means the conjugate is uninteresting as a research chemical. It means the honest description is "an unpublished N-terminal adamantane derivative of Semax, supplied with a certificate of identity and purity," and that any laboratory working with it is generating the first characterization data rather than confirming prior results.

Frequently Asked Questions

What is Adamax and how is it different from Semax?

Adamax is a vendor name for Semax (Met-Glu-His-Phe-Pro-Gly-Pro) with an adamantane cage attached, usually at the N-terminal amine. The addition raises the mass from about 814 to about 976 daltons, removes the free N-terminal amine, and makes the molecule far more lipophilic. It has no published biology of its own.

Are there any published studies on Adamax?

No. A PubMed search for "Adamax" returns only papers on the AdaMax machine-learning optimizer, and searches for adamantane-conjugated Semax return nothing. The relevant evidence is indirect: the Semax parent literature and medicinal-chemistry papers on adamantane conjugation of other peptides.

Why would anyone attach adamantane to a peptide?

Medicinal chemists add the adamantane cage to raise lipophilicity, fill hydrophobic binding pockets, and shield adjacent bonds from enzymes, as reviewed by Wanka and colleagues in Chemical Reviews (2013). Peptide examples include enkephalin conjugates (Kitagawa 1997) and adamantyl peptide nucleic acids (Ljungstrom 1999), where uptake rose but depended on the cell line.

How can I tell whether a vial labeled Adamax actually contains the conjugate?

Read the mass-spectrometry identity line on the lot certificate. Adamantoyl-Semax should show an observed mass near 976 daltons; a value near 814 means the vial is plain Semax. The conjugate should also elute later than Semax on reverse-phase HPLC because of its much higher hydrophobicity.

Citations

1. Dolotov OV, Karpenko EA, Seredenina TS, et al. Semax, an analogue of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain. J Neurochem. 2006;97 Suppl 1:82-86. PMID 16635254
2. Dolotov OV, Karpenko EA, Inozemtseva LS, et al. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Res. 2006;1117:54-60. PMID 16996037
3. Shevchenko KV, Nagaev IY, Alfeeva LY, et al. Kinetics of Semax penetration into the brain and blood of rats after its intranasal administration [in Russian]. Bioorg Khim. 2006;32:64-70. PMID 16523722
4. Zolotarev YA, Dadayan AK, Dolotov OV, et al. Evenly tritium-labeled peptides and their in vivo and in vitro biodegradation [in Russian]. Bioorg Khim. 2006;32:183-191. PMID 16637290
5. Shevchenko KV, Nagaev IY, Andreeva LA, Shevchenko VP, Myasoedov NF. Stability of Semax acetyl to proteolysis in various biological media. Dokl Biol Sci. 2013;449:110-112. PMID 23652441
6. Magri A, Tabbi G, Giuffrida A, et al. Influence of the N-terminus acetylation of Semax, a synthetic analog of ACTH(4-10), on copper(II) and zinc(II) coordination and biological properties. J Inorg Biochem. 2016;164:59-69. PMID 27586814
7. Wanka L, Iqbal K, Schreiner PR. The lipophilic bullet hits the targets: medicinal chemistry of adamantane derivatives. Chem Rev. 2013;113:3516-3604. PMID 23432396
8. Ragshaniya A, et al. Nascent pharmacological advancement in adamantane derivatives. Arch Pharm (Weinheim). 2024;357:e2300595. PMID 38128028
9. Kitagawa K, Mizobuchi N, Hama T, Hibi T, Konishi R, Futaki S. Synthesis and antinociceptive activity of [D-Ala2]Leu-enkephalin derivatives conjugated with the adamantane moiety. Chem Pharm Bull (Tokyo). 1997;45:1782-1787. PMID 9396154
10. Ljungstrom T, Knudsen H, Nielsen PE. Cellular uptake of adamantyl conjugated peptide nucleic acids. Bioconjug Chem. 1999;10:965-972. PMID 10563765
11. Kapoerchan VV, Knijnenburg AD, Niamat M, et al. An adamantyl amino acid containing gramicidin S analogue with broad spectrum antibacterial activity and reduced hemolytic activity. Chemistry. 2010;16:12174-12181. PMID 20848624
12. Todorov P, Peneva P, Tchekalarova J, Georgieva S, Rangelov M, Todorova N. Structure-activity relationship study on new hemorphin-4 analogues containing steric restricted amino acids moiety for evaluation of their anticonvulsant activity. Amino Acids. 2020;52:1375-1390. PMID 33011823
13. Karle IL, Ranganathan D, Kumar MG, Nagaraj R. Design, synthesis, conformational and membrane ion transport studies of proline-adamantane hybrid cyclic depsipeptides. Biopolymers. 2008;89:471-478. PMID 18067153
14. Radchenko AI, Kuzubova EV, Apostol AA, et al. The Potential of the Peptide Drug Semax and Its Derivative for Correcting Pathological Impairments in the Animal Model of Alzheimer's Disease. Acta Naturae. 2025;17:110-120. PMID 41479572

This article is for laboratory research reference only. US Prime Peptides products are supplied strictly for in vitro research. Not for human consumption.

Compliance Notice: US Prime Peptides products are supplied strictly for laboratory and academic research purposes only. They are not intended for human or veterinary consumption, diagnosis, treatment, or prevention of any disease. All content on this page is educational in nature and does not constitute medical advice or product claims. Researchers are responsible for handling these compounds in accordance with their institution’s safety protocols and applicable laws.